AIM ImmunoTech Files 8-K for Material Agreement
Ticker: AIM · Form: 8-K · Filed: Oct 29, 2025 · CIK: 946644
Sentiment: neutral
Topics: material-agreement, filing
TL;DR
AIM ImmunoTech signed a big deal, filing an 8-K on Oct 29, 2025.
AI Summary
AIM ImmunoTech Inc. filed an 8-K on October 29, 2025, reporting an entry into a material definitive agreement and filing financial statements and exhibits. The company, formerly known as Hemispherx Biopharma Inc., is based in Ocala, Florida, and operates in the biological products sector.
Why It Matters
This filing indicates a significant new agreement for AIM ImmunoTech, which could impact its financial performance and strategic direction.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that are not yet fully understood by the market.
Key Players & Entities
- AIM ImmunoTech Inc. (company) — Registrant
- October 29, 2025 (date) — Date of earliest event reported
- Hemispherx Biopharma Inc. (company) — Former company name
- Ocala, FL (location) — Principal executive offices
FAQ
What type of material definitive agreement did AIM ImmunoTech Inc. enter into?
The filing states an 'Entry into a Material Definitive Agreement' as an item information, but the specific details of the agreement are not provided in this excerpt.
When was the report filed and what is the earliest event date?
The report was filed on October 29, 2025, and the earliest event reported is also October 29, 2025.
What is the principal business address of AIM ImmunoTech Inc.?
The principal executive offices are located at 2117 SW Highway 484, Ocala, FL 34473.
What was AIM ImmunoTech Inc. formerly known as?
The company was formerly known as HEMISPHERX BIOPHARMA INC.
What is the SIC code for AIM ImmunoTech Inc.?
The Standard Industrial Classification (SIC) code is 2836, for BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 430 words · 2 min read · ~1 pages · Grade level 10.6 · Accepted 2025-10-29 17:16:06
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share AIM NYSE American Item
Filing Documents
- form8-k.htm (8-K) — 38KB
- ex3-1_i.htm (EX-3.1_I) — 128KB
- ex3-1i_001.jpg (GRAPHIC) — 152KB
- ex3-1i_002.jpg (GRAPHIC) — 148KB
- ex3-1i_003.jpg (GRAPHIC) — 136KB
- ex3-1i_004.jpg (GRAPHIC) — 126KB
- ex3-1i_005.jpg (GRAPHIC) — 273KB
- ex3-1i_006.jpg (GRAPHIC) — 305KB
- ex3-1i_007.jpg (GRAPHIC) — 266KB
- ex3-1i_008.jpg (GRAPHIC) — 345KB
- ex3-1i_009.jpg (GRAPHIC) — 76KB
- ex3-1i_010.jpg (GRAPHIC) — 263KB
- ex3-1i_011.jpg (GRAPHIC) — 336KB
- ex3-1i_012.jpg (GRAPHIC) — 365KB
- ex3-1i_013.jpg (GRAPHIC) — 333KB
- ex3-1i_014.jpg (GRAPHIC) — 368KB
- ex3-1i_015.jpg (GRAPHIC) — 327KB
- ex3-1i_016.jpg (GRAPHIC) — 342KB
- ex3-1i_017.jpg (GRAPHIC) — 369KB
- ex3-1i_018.jpg (GRAPHIC) — 341KB
- ex3-1i_019.jpg (GRAPHIC) — 315KB
- ex3-1i_020.jpg (GRAPHIC) — 367KB
- ex3-1i_021.jpg (GRAPHIC) — 336KB
- ex3-1i_022.jpg (GRAPHIC) — 366KB
- ex3-1i_023.jpg (GRAPHIC) — 326KB
- ex3-1i_024.jpg (GRAPHIC) — 383KB
- ex3-1i_025.jpg (GRAPHIC) — 378KB
- ex3-1i_026.jpg (GRAPHIC) — 362KB
- ex3-1i_027.jpg (GRAPHIC) — 375KB
- ex3-1i_028.jpg (GRAPHIC) — 375KB
- ex3-1i_029.jpg (GRAPHIC) — 352KB
- ex3-1i_030.jpg (GRAPHIC) — 319KB
- ex3-1i_031.jpg (GRAPHIC) — 321KB
- ex3-1i_032.jpg (GRAPHIC) — 376KB
- ex3-1i_033.jpg (GRAPHIC) — 293KB
- ex3-1i_034.jpg (GRAPHIC) — 371KB
- ex3-1i_035.jpg (GRAPHIC) — 287KB
- ex3-1i_036.jpg (GRAPHIC) — 49KB
- ex3-1i_037.jpg (GRAPHIC) — 245KB
- ex3-1i_038.jpg (GRAPHIC) — 333KB
- ex3-1i_039.jpg (GRAPHIC) — 322KB
- ex3-1i_040.jpg (GRAPHIC) — 117KB
- ex3-1i_041.jpg (GRAPHIC) — 184KB
- ex3-1i_042.jpg (GRAPHIC) — 202KB
- ex3-1i_043.jpg (GRAPHIC) — 260KB
- ex3-1i_044.jpg (GRAPHIC) — 302KB
- ex3-1i_045.jpg (GRAPHIC) — 343KB
- ex3-1i_046.jpg (GRAPHIC) — 299KB
- ex3-1i_047.jpg (GRAPHIC) — 326KB
- ex3-1i_048.jpg (GRAPHIC) — 316KB
- ex3-1i_049.jpg (GRAPHIC) — 311KB
- ex3-1i_050.jpg (GRAPHIC) — 342KB
- ex3-1i_051.jpg (GRAPHIC) — 318KB
- ex3-1i_052.jpg (GRAPHIC) — 275KB
- ex3-1i_053.jpg (GRAPHIC) — 324KB
- ex3-1i_054.jpg (GRAPHIC) — 318KB
- ex3-1i_055.jpg (GRAPHIC) — 341KB
- ex3-1i_056.jpg (GRAPHIC) — 319KB
- ex3-1i_057.jpg (GRAPHIC) — 346KB
- ex3-1i_058.jpg (GRAPHIC) — 349KB
- ex3-1i_059.jpg (GRAPHIC) — 336KB
- ex3-1i_060.jpg (GRAPHIC) — 360KB
- ex3-1i_061.jpg (GRAPHIC) — 316KB
- ex3-1i_062.jpg (GRAPHIC) — 359KB
- ex3-1i_063.jpg (GRAPHIC) — 344KB
- ex3-1i_064.jpg (GRAPHIC) — 300KB
- ex3-1i_065.jpg (GRAPHIC) — 291KB
- ex3-1i_066.jpg (GRAPHIC) — 163KB
- ex3-1i_067.jpg (GRAPHIC) — 206KB
- ex3-1i_068.jpg (GRAPHIC) — 228KB
- ex3-1i_069.jpg (GRAPHIC) — 308KB
- ex3-1i_070.jpg (GRAPHIC) — 337KB
- ex3-1i_071.jpg (GRAPHIC) — 300KB
- ex3-1i_072.jpg (GRAPHIC) — 345KB
- ex3-1i_073.jpg (GRAPHIC) — 331KB
- ex3-1i_074.jpg (GRAPHIC) — 316KB
- ex3-1i_075.jpg (GRAPHIC) — 336KB
- ex3-1i_076.jpg (GRAPHIC) — 300KB
- ex3-1i_077.jpg (GRAPHIC) — 295KB
- ex3-1i_078.jpg (GRAPHIC) — 336KB
- ex3-1i_079.jpg (GRAPHIC) — 325KB
- ex3-1i_080.jpg (GRAPHIC) — 338KB
- ex3-1i_081.jpg (GRAPHIC) — 313KB
- ex3-1i_082.jpg (GRAPHIC) — 355KB
- ex3-1i_083.jpg (GRAPHIC) — 356KB
- ex3-1i_084.jpg (GRAPHIC) — 324KB
- ex3-1i_085.jpg (GRAPHIC) — 366KB
- ex3-1i_086.jpg (GRAPHIC) — 321KB
- ex3-1i_087.jpg (GRAPHIC) — 338KB
- ex3-1i_088.jpg (GRAPHIC) — 334KB
- ex3-1i_089.jpg (GRAPHIC) — 286KB
- ex3-1i_090.jpg (GRAPHIC) — 294KB
- ex3-1i_091.jpg (GRAPHIC) — 153KB
- ex3-1i_092.jpg (GRAPHIC) — 226KB
- ex3-1i_093.jpg (GRAPHIC) — 246KB
- ex3-1i_094.jpg (GRAPHIC) — 284KB
- ex3-1i_095.jpg (GRAPHIC) — 278KB
- ex3-1i_096.jpg (GRAPHIC) — 180KB
- ex3-1i_097.jpg (GRAPHIC) — 147KB
- ex3-1i_098.jpg (GRAPHIC) — 173KB
- ex3-1i_099.jpg (GRAPHIC) — 190KB
- ex3-1i_100.jpg (GRAPHIC) — 211KB
- ex3-1i_101.jpg (GRAPHIC) — 89KB
- ex3-1i_102.jpg (GRAPHIC) — 203KB
- ex3-1i_103.jpg (GRAPHIC) — 214KB
- ex3-1i_104.jpg (GRAPHIC) — 203KB
- ex3-1i_105.jpg (GRAPHIC) — 269KB
- ex3-1i_106.jpg (GRAPHIC) — 379KB
- ex3-1i_107.jpg (GRAPHIC) — 377KB
- ex3-1i_108.jpg (GRAPHIC) — 319KB
- ex3-1i_109.jpg (GRAPHIC) — 371KB
- ex3-1i_110.jpg (GRAPHIC) — 383KB
- ex3-1i_111.jpg (GRAPHIC) — 386KB
- ex3-1i_112.jpg (GRAPHIC) — 397KB
- ex3-1i_113.jpg (GRAPHIC) — 368KB
- ex3-1i_114.jpg (GRAPHIC) — 317KB
- ex3-1i_115.jpg (GRAPHIC) — 391KB
- ex3-1i_116.jpg (GRAPHIC) — 395KB
- ex3-1i_117.jpg (GRAPHIC) — 382KB
- ex3-1i_118.jpg (GRAPHIC) — 254KB
- ex3-1i_119.jpg (GRAPHIC) — 259KB
- ex3-1i_120.jpg (GRAPHIC) — 377KB
- ex3-1i_121.jpg (GRAPHIC) — 402KB
- ex3-1i_122.jpg (GRAPHIC) — 401KB
- ex3-1i_123.jpg (GRAPHIC) — 381KB
- ex3-1i_124.jpg (GRAPHIC) — 234KB
- ex3-1i_125.jpg (GRAPHIC) — 59KB
- ex3-1i_126.jpg (GRAPHIC) — 194KB
- ex3-1i_127.jpg (GRAPHIC) — 188KB
- ex3-1i_128.jpg (GRAPHIC) — 189KB
- ex3-1i_129.jpg (GRAPHIC) — 224KB
- ex3-1i_130.jpg (GRAPHIC) — 255KB
- ex3-1i_131.jpg (GRAPHIC) — 248KB
- ex3-1i_132.jpg (GRAPHIC) — 78KB
- ex3-1i_133.jpg (GRAPHIC) — 179KB
- ex3-1i_134.jpg (GRAPHIC) — 278KB
- ex3-1i_135.jpg (GRAPHIC) — 276KB
- ex3-1i_136.jpg (GRAPHIC) — 246KB
- ex3-1i_137.jpg (GRAPHIC) — 253KB
- ex3-1i_138.jpg (GRAPHIC) — 224KB
- ex3-1i_139.jpg (GRAPHIC) — 237KB
- ex3-1i_140.jpg (GRAPHIC) — 302KB
- ex3-1i_141.jpg (GRAPHIC) — 266KB
- ex3-1i_142.jpg (GRAPHIC) — 44KB
- ex3-1i_143.jpg (GRAPHIC) — 51KB
- ex3-1i_144.jpg (GRAPHIC) — 185KB
- ex3-1i_145.jpg (GRAPHIC) — 191KB
- ex3-1i_146.jpg (GRAPHIC) — 217KB
- ex3-1i_147.jpg (GRAPHIC) — 37KB
- ex3-1i_148.jpg (GRAPHIC) — 145KB
- ex3-1i_149.jpg (GRAPHIC) — 249KB
- ex3-1i_150.jpg (GRAPHIC) — 374KB
- ex3-1i_151.jpg (GRAPHIC) — 370KB
- ex3-1i_152.jpg (GRAPHIC) — 323KB
- ex3-1i_153.jpg (GRAPHIC) — 337KB
- ex3-1i_154.jpg (GRAPHIC) — 279KB
- ex3-1i_155.jpg (GRAPHIC) — 45KB
- ex3-1i_156.jpg (GRAPHIC) — 221KB
- ex3-1i_157.jpg (GRAPHIC) — 192KB
- ex3-1i_158.jpg (GRAPHIC) — 48KB
- ex3-1i_159.jpg (GRAPHIC) — 248KB
- ex3-1i_160.jpg (GRAPHIC) — 304KB
- ex3-1i_161.jpg (GRAPHIC) — 334KB
- ex3-1i_162.jpg (GRAPHIC) — 285KB
- ex3-1i_163.jpg (GRAPHIC) — 313KB
- ex3-1i_164.jpg (GRAPHIC) — 175KB
- ex3-1i_165.jpg (GRAPHIC) — 204KB
- ex3-1i_166.jpg (GRAPHIC) — 197KB
- ex3-1i_167.jpg (GRAPHIC) — 184KB
- ex3-1i_168.jpg (GRAPHIC) — 228KB
- ex3-1i_169.jpg (GRAPHIC) — 294KB
- ex3-1i_170.jpg (GRAPHIC) — 309KB
- ex3-1i_171.jpg (GRAPHIC) — 275KB
- ex3-1i_172.jpg (GRAPHIC) — 324KB
- ex3-1i_173.jpg (GRAPHIC) — 307KB
- ex3-1i_174.jpg (GRAPHIC) — 333KB
- ex3-1i_175.jpg (GRAPHIC) — 322KB
- ex3-1i_176.jpg (GRAPHIC) — 337KB
- ex3-1i_177.jpg (GRAPHIC) — 350KB
- ex3-1i_178.jpg (GRAPHIC) — 360KB
- ex3-1i_179.jpg (GRAPHIC) — 288KB
- ex3-1i_180.jpg (GRAPHIC) — 307KB
- ex3-1i_181.jpg (GRAPHIC) — 326KB
- ex3-1i_182.jpg (GRAPHIC) — 170KB
- ex3-1i_183.jpg (GRAPHIC) — 77KB
- ex3-1i_184.jpg (GRAPHIC) — 152KB
- ex3-1i_185.jpg (GRAPHIC) — 215KB
- ex3-1i_186.jpg (GRAPHIC) — 134KB
- ex3-1i_187.jpg (GRAPHIC) — 171KB
- ex3-1i_188.jpg (GRAPHIC) — 80KB
- ex3-1i_189.jpg (GRAPHIC) — 274KB
- ex3-1i_190.jpg (GRAPHIC) — 294KB
- ex3-1i_191.jpg (GRAPHIC) — 330KB
- 0001493152-25-020102.txt ( ) — 72943KB
- aim-20251029.xsd (EX-101.SCH) — 3KB
- aim-20251029_lab.xml (EX-101.LAB) — 33KB
- aim-20251029_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AIM ImmunoTech Inc. Date: October 29, 2025 By /s/ Thomas K. Equels Thomas K. Equels, CEO